1. Home
  2. Companies
  3. NXN
  4. Material Events

Nexsen (ASX:NXN) — Material Events

ASX:NXN · 14 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 12 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
12
Nexsen Launches Clinical Trial for StrepSure® GBS Sensor, Eyeing 2026 Market EntryMedium
Nexsen launches clinical trial for StrepSure® GBS Rapid Sensor targeting early market entry in 2H 2026
21 Oct 2025 ·Clinical Trial Announcement ·85
Nexsen Links with Hong Kong Hospital to Advance Rapid Diagnostic ValidationMedium
Nexsen secures strategic hospital partnership in Asia with GHK Hospital to advance rapid diagnostic platform
13 May 2026 ·Strategic Partnership Announcement ·85
Nexsen Advances FDA Pathway for Rapid GBS Sensor with New CFO OnboardMedium
Nexsen starts FDA engagement for GBS rapid sensor, appoints CFO, and gains scientific recognition
6 Jan 2026 ·Business Update ·85
Nexsen Targets FDA Submission as StrepSure® Global Rollout AcceleratesMedium
Nexsen accelerates StrepSure® global rollout with FDA submission targeted for Q4 2026
26 Mar 2026 ·ASX Release ·85
Nexsen Raises $8M, Advances Kidney Diagnostics, and Launches GBS Sensor TrialsHigh
Nexsen raises $8M in IPO, advances diagnostics, and starts GBS Rapid Sensor clinical trials
31 Oct 2025 ·Quarterly Activity and Appendix 4C Cash Flow Report ·85
Nexsen Advances StrepSure FDA Pathway and Secures Key Asia-Pacific GrantsMedium
Nexsen clears FDA regulatory hurdle for StrepSure®, secures grants, and advances global rollout
28 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·85
Nexsen Clears FDA Hurdle, Paving Way for StrepSure® in US Maternal Health MarketMedium
Nexsen achieves key FDA milestone, de-risking U.S. approval path for StrepSure® diagnostic
23 Mar 2026 ·Regulatory Update ·85
Nexsen Advances Rapid Diagnostics with FDA Pre-Submission and Strong Cash PositionMedium
Nexsen advances rapid diagnostics with FDA pre-submission and strong cash position post-IPO
29 Jan 2026 ·Appendix 4C Quarterly Cash Flow Report and Quarterly Activities Report ·85
Nexsen Secures $500K Grant to Advance Neonatal GBS DiagnosticMedium
Nexsen secures $500K grant to expand rapid GBS diagnostic into neonatal care
27 Jan 2026 ·ASX Release ·80
Nexsen and Universiti Malaya Target Rapid Dual Biosensor for Food SafetyMedium
Nexsen and Universiti Malaya launch joint research facility to develop rapid foodborne pathogen biosensor
4 May 2026 ·Partnership Announcement ·75
Nexsen Secures HK$6 Million Grant to Boost Asia-Pacific Diagnostic RolloutMedium
Nexsen secures HK$6 million grant to advance Asia-Pacific rollout of StrepSure® diagnostic
31 Mar 2026 ·Grant Announcement ·75
Nexsen Taps Global Surgeon-Scientist to Accelerate 2026 Market LaunchMedium
Nexsen appoints Professor Shekhar Kumta to board to boost global clinical and regulatory strategy ahead of 2026 market entry
3 Dec 2025 ·Board Appointment ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.